Developing a safer vaccine for Argentine hemorrhagic fever
Rational design of a safe recombinant Candid#1 vaccine
This study is working on a new vaccine for the Junín virus, which causes Argentine hemorrhagic fever, to make sure it’s safe and effective for people at risk of getting the disease from rodents.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project ID | NIH-10814162 on NIH RePORTER |
What this research studies
This research focuses on creating a recombinant vaccine for the Junín virus, which causes Argentine hemorrhagic fever, a serious disease transmitted from rodents to humans. The current vaccine used in Argentina has safety concerns due to the potential for the virus to revert to a more dangerous form. The researchers aim to design a new vaccine that maintains its safety while still providing effective protection against the virus. They are utilizing advanced genetic techniques to ensure that the vaccine remains stable and effective in eliciting an immune response.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of exposure to the Junín virus, particularly those living in or traveling to endemic areas.
Not a fit: Patients who are not at risk of exposure to the Junín virus or who have already been vaccinated with the current vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective vaccine for Argentine hemorrhagic fever, potentially saving lives and improving public health.
How similar studies have performed: Previous research has shown promise in developing safer vaccines for similar viral infections, indicating that this approach could be successful.
Where this research is happening
Missoula, United States
- University of Montana — Missoula, United States (Active)
Researchers
- Principal investigator: Nunberg, Jack H — University of Montana
- Study coordinator: Nunberg, Jack H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.